Altea signs Japanese deal for transdermal patch development
Altea Therapeutics of Atlanta and Teikoku Seiyaku Co in Japan are to jointly develop a transdermal therapy for Parkinson's disease. Altea has agreed an exclusive licensing deal for Japan with Teikoku Seiyaku for the patch therapy.
Altea Therapeutics of Atlanta and Teikoku Seiyaku Co in Japan are to jointly develop a transdermal therapy for Parkinson's disease. Altea has agreed an exclusive licensing deal for Japan with Teikoku Seiyaku for the patch therapy.
Teikoku Seiyaku, headquartered in Kagawa, is a leading manufacturer of medicated patches and a pioneer in the field of anti-inflammatory and analgesic plasters. It will use Altea's PassPort transdermal technology to deliver an active pharmaceutical ingredient for managing Parkinson's disease.
Under the agreement, Teikoku Seiyaku will pay Altea a signing fee and additional payments upon completion of development milestones. It will also pay undisclosed royalties on net sales and revenues and also fund the cost of Japanese product development.
'This is a first in what is expected to be a number of collaborations based on our proprietary PassPort System technology that enables painless, efficient transdermal delivery of sustained therapeutic levels of proteins and water-soluble molecules from a skin patch', said Eric Tomlinson, president and ceo of Altea Therapeutics.